Stelara

This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.

Sun Pharma passes milestone with novel psoriasis drug approval

Johnson &Johnson's IL-12/IL-23 blocker Stelara (ustekinumab) was the first interleukin drug to reach the market and swiftly reached blockbuster sales level, and has since been joined by

Latest news

AbbVie reports more solid data for would-be psoriasis blockbuster

AbbVie reports more solid data for would-be psoriasis blockbuster. Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara. ... A pair of phase III trials pitting risankizumab against Johnson &Johnson’s older
Janssen’s Tremfya cleared for European use

therapy. The drug is a follow-up for its IL-23/IL-12 inhibitor Stelara, which is facing competition from newer psoriasis drugs showing greater efficacies in clinical trials.
AbbVie risankizumab trials set up psoriasis filing - and a market battle

Competes against blockbusters Stelara and Humira. AbbVie has posted a trio of positive phase III trials for its interleukin-23 inhibitor risankizumab, setting up regulatory applications but also a tough entry ... The anti-interleukin-23 (IL-23) antibody
European Commission backs LEO Pharma’s Kyntheum

compared to 19-22% on Johnson &Johnson’s Stelara (ustekinumab).
Biosimilars eat into J&J's Remicade sales

trials - Stelara still grew more than 22% to $983m in the second quarter. ... The company reckons Tremfya combines good efficacy with "Stelara-like safety" and a less intensive dosing regimen that will stand it in good stead in the market.

More from news
Approximately 14 fully matching, plus 55 partially matching documents found.

Latest Intelligence

Taking a strategic approach

Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for
Back to the future

Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Account Manager / Account Director: Great salary and bebefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Account Manager – Med Comms – London: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Editorial Director – Medical Education – Oxford: Negotiable

Senior Account Manager – Med Comms – Kent: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editor – Medical Education Agency – Bucks: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Programme Executive: Salary TBC

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Account Manager or AD - Medical Communications: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer: Great salary and bebefits

Senior Medical Writer: Great salary and benefits

Scientific Director: Great salary and bebefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Subscribe to our email news alerts

PMHub

Add my company

FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...